← 返回

基于基因的 NK 细胞疗法治疗儿童血液系统恶性肿瘤

英文原题:Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies.

查看英文原题

Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies.

PubMed 2022/06/27(内容时间) Hematol Oncol Clin North Am Q2 · IF 3.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

儿童血液癌症是儿童常见恶性肿瘤之一。许多病例无法通过强化化疗治愈,亟需新型疗法。由于安全性较好、具有内在细胞毒性且可通过基因修饰增强特异性和杀伤能力,NK细胞有望成为免疫治疗效应细胞。NK细胞可经工程化表达靶向肿瘤特异性抗原的CAR、下调抑制及调节信号、分泌细胞因子,并优化其与小分子衔接剂的相互作用。了解NK细胞生物学是设计可转化至临床的免疫疗法的关键。

展开英文摘要原文

Pediatric blood cancers are among the most common malignancies that afflict children. Intensive chemotherapy is not curative in many cases, and novel therapies are urgently needed. NK cells hold promise for use as immunotherapeutic effectors due to their favorable safety profile, intrinsic cytotoxic properties, and potential for genetic modification that can enhance specificity and killing potential.

NK cells can be engineered to express CARs targeting tumor-specific antigens, to downregulate inhibitory and regulatory signals, to secrete cytokine, and to optimize interaction with small molecule engagers. Understanding NK cell biology is key to designing immunotherapy for clinical translation.

论文信息

作者
Rahnama R、Christodoulou I、Bonifant CL
第一作者单位
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21287, USA; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.United States
通讯作者单位
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21287, USA; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: cbonifa2@jh.edu.United States
文献类型
综述 · 非美国政府资助研究
期刊
Hematology/oncology clinics of North America2022 Aug
原文标识
PubMed 35773048 · DOI 10.1016/j.hoc.2022.03.007